PGA-timolol combo effective for POAG

Article

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

A combination of prostaglandin analog (PGA) and timolol 0.1 & gel reduces both IOP and fluctuations in primary-angle glaucoma patients, states a recent paper in European Journal of Ophthalmology.

Dr Carlo Nucci et al., Ophthalmology Unit, Department of Exp. Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, administered fixed combinations of PGA-timolol in 64 eyes of 32 patients. This included 17 patients receiving a latanoprost-timolol fixed combination, 9 patients receiving a travoprost-timolol fixed combination and six who were administered bimatoprost-timolol fixed combination. The primary endpoint was the comparison between efficacy of fixed and unfixed combinations in lowering IOP and short-term IOP fluctuations.

All unfixed treatment combinations induced an IOP reduction that was significantly higher than the corresponding fixed treatment combinations. IOP diurnal fluctuations significantly decreased after unfixed combinations were administered, as well as increasing the percentage of patients with daily IOP fluctuation of 2 mm or less.

PGA and timolol was the most effective POAG treatment when administered as an unfixed combination. Once saily timolol 0.1% gel is a valuable treatment option as it reduces both IOP and daily fluctuations.

To read the journal abstract please click here.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.